Piper Sandler & Co’s Heron Therapeutics HRTX Stock Holding History

Piper Sandler & Co’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-27	Closed	–	–	148
2014 Q2	$0	Buy	+27	New	+$323	﹤0.01%	132

Other funds holding HRTX

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Franklin Resources

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Piper Sandler & Co's HRTX Position: Q3 2014 in Review

Piper Sandler & Co sold out of Heron Therapeutics (HRTX) in Q3 2014, closing a stake of 27 shares.

Piper Sandler & Co first reported a position in HRTX in Q2 2014 and held it in 1 quarter. The position peaked at $0 in Q2 2014. 59 funds tracked by Wall St. Rank hold HRTX as of Q3 2014.

Piper Sandler & Co reported no remaining Heron Therapeutics position as of Q3 2014 after selling out during the quarter.
Piper Sandler & Co sold 27 Heron Therapeutics shares in Q3 2014.
Piper Sandler & Co first reported a position in Heron Therapeutics in Q2 2014 and held it in 1 quarter.
Piper Sandler & Co's Heron Therapeutics position peaked at $0 in Q2 2014.
59 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2014.

Based on Piper Sandler & Co's 13F filing for Q3 2014, filed 14 Nov 2014.